New directions with hormone therapy in prostate cancer: possible benefit from blocking prolactin and use of hormone treatment intermittently in combination with immunotherapy

Oliver, R.T.D.

doi:10.1016/0959-8049(95)00231-6

European Journal of Cancer

1995

DOI: 10.1016/0959-8049(95)00231-6

|View full text |Cite

New directions with hormone therapy in prostate cancer: possible benefit from blocking prolactin and use of hormone treatment intermittently in combination with immunotherapy

R.T.D. Oliver

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1995

1999

Publication Types

Select...

Article4

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

A preliminary report on the use of transfer factor for treating stage D3 hormone-unresponsive metastatic prostate cancer

et al. 1996

View full text Add to dashboard Cite

As conventional treatments are unsuccessful, the survival rate of stage D3 prostate cancer patients is poor. Reports have suggested the existence of humoral and cell-mediated immunity (CMI) against prostate cancer tumour-associated antigens (TAA). These observations prompted us to treat stage D3 prostate cancer patients with an in vitro produced transfer factor (TF) able to transfer, in vitro and in vivo, CMI against bladder and prostate TAA. Fifty patients entered this study and received one intramuscular injection of 2-5 units of specific TF monthly. Follow-up, ranging from 1 to 9 years, showed that complete remission was achieved in 2 patients, partial remission in 6, and no progression of metastatic disease in 14. The median survival was 126 weeks, higher than the survival rates reported in the literature for patients of the same stage.

show abstract

A preliminary report on the use of transfer factor for treating stage D3 hormone-unresponsive metastatic prostate cancer

et al. 1996

View full text Add to dashboard Cite

show abstract

Intermittent hormone therapy in prostate and breast cancers

Stoll

1995

European Journal of Cancer

View full text Add to dashboard Cite

Does surgery disseminate or accelerate cancer?

Oliver

1995

The Lancet

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

New directions with hormone therapy in prostate cancer: possible benefit from blocking prolactin and use of hormone treatment intermittently in combination with immunotherapy

Cited by 4 publications

References 11 publications

A preliminary report on the use of transfer factor for treating stage D3 hormone-unresponsive metastatic prostate cancer

A preliminary report on the use of transfer factor for treating stage D3 hormone-unresponsive metastatic prostate cancer

Intermittent hormone therapy in prostate and breast cancers

Does surgery disseminate or accelerate cancer?

Contact Info

Product

Resources

About